By Dr. Lan Huang via Life Science Leader:
“While the pharmaceutical industry is under increased pressure and faced with various serious issues, (e.g., drug pricing woes and changing FDA regulations) now, more than ever, the industry is ripe for improvement and innovation.
Big Data, for example, has a huge potential to improve patient care, while value-based pricing will become more of the standard for reimbursement. In addition, the Nobel Prize-winning field of ubiquitination-mediated protein degradation, the topic of the keynote at the 2016 ASCO conference, holds great promise for treating 70 percent of undruggable targets in the cell, plus is the mechanism of Revlimid, a $7 billion blockbuster and the first two of many pharma partnership deals.
The following explain why each of these topics will be important focus areas for the pharmaceutical industry in the near future.
Big Data To The Rescue
In the future, computers and/or robots will analyze Big Data from patient diagnoses to select the best drug for an individual cancer patient and prescribe better follow-up medicine to contain the disease. With the tremendous advancement of diagnoses that are using liquid biopsy, we also will have a large amount of data from individual cancer patients.”